Adenosquamous carcinoma of the lung
Jump to navigation
Jump to search
Adenosquamous carcinoma of the lung, also lung adenosquamous carcinoma, is a rare epithelial derived malignancy of the lung with features of both adenocarcinoma and squamous cell carcinoma.
| Adenosquamous carcinoma of the lung | |
|---|---|
| Diagnosis in short | |
 Adenosquamous carcinoma of lung. H&E stain. | |
| LM DDx | squamous cell carcinoma of the lung, adenocarcinoma of the lung |
| Site | lung - see lung tumours |
|
| |
| Prevalence | rare |
| Clin. DDx | other lung tumours |
It is grouped with the non-small cell lung cancers.
General
- Rare.
- Respond to tyrosine kinase inhibitors.[1][2]
Microscopic
Features:
- Adenocarcinoma component.
- Squamous cell carcinoma component.
DDx:
Images
ASC - intermed. mag. (WC)
ASC - intermed. mag. (WC)
ASC - high mag. (WC)
ASC - very high mag. (WC)
www
Sign out
Biopsy - possible adenosquamous carcinoma
Left Upper Lobe of Lung, Core Biopsy:
- NONSMALL CELL CARCINOMA, FAVOUR ADENOCARCINOMA, CANNOT EXCLUDE ADENOSQUAMOUS CARCINOMA.
Comment:
The tumour stains as follow:
POSITIVE: TTF-1, CK5/6 (focal), p63, napsin A.
NEGATIVE: (none).
The positive staining (TTF-1 and napsin A versus CK5/6 and p63) appears to be in different tumour cells.
The case was reviewed internally and there is agreement on the above interpretation.
Note:
- Cases should not be signed as adenosquamous carcinoma on biopsy, due to the percentage requirements of the diagnosis.
See also
References
- ↑ Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.
- ↑ Iwanaga, K.; Sueoka-Aragane, N.; Nakamura, T.; Mori, D.; Kimura, S. (2012). "The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.". Intern Med 51 (19): 2771-4. PMID 23037472.